Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial.

Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial.

BACKGROUND:Use of everolimus-eluting stents (EES) has proven to be clinically effective and safe in patients with ST-segment elevation myocardial infarction but it remains unclear whether it is cost-effective compared to bare-metal stents (BMS) in the long-term. We sought to assess the cost-effectiv...

Full description

Bibliographic Details
Main Authors:	Nadine Schur, Salvatore Brugaletta, Angel Cequier, Andrés Iñiguez, Antonio Serra, Pilar Jiménez-Quevedo, Vicente Mainar, Gianluca Campo, Maurizio Tespili, Peter den Heijer, Armando Bethencourt, Nicolás Vazquez, Marco Valgimigli, Patrick W Serruys, Zanfina Ademi, Matthias Schwenkglenks, Manel Sabaté
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2018-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC6095536?pdf=render

Similar Items

Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes
by: Panoulas VF, et al.
Published: (2015-07-01)

Everolimus-eluting coronary stents
by: Alejandro Saez, et al.
Published: (2010-09-01)

Everolimus-eluting stents in interventional cardiology
by: Townsend JC, et al.
Published: (2012-06-01)

Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform
by: Matthew G. Whitbeck, et al.
Published: (2013-07-01)

Second Generation Drug-Eluting Stents: A Review of the Everolimus-Eluting Platform
by: Matthew G. Whitbeck, et al.
Published: (2013-01-01)

Everolimus-eluting stents: update on current clinical studies
by: Allocco DJ, et al.
Published: (2011-07-01)

Stent Fracture after Everolimus-Eluting Stent Implantation
by: Ali S. Almasood, et al.
Published: (2011-01-01)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®)
by: Imad Sheiban, et al.
Published: (2008-02-01)

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
by: Hang Ouyang, et al.
Published: (2021-04-01)

Midterm Clinical Impacts of Biodegradable Polymer Everolimus-Eluting Stents Compared with Durable Polymer Everolimus-Eluting Stents: A 3-Year Propensity-Matched Study
by: Hiroaki Matsuda, et al.
Published: (2020-01-01)

Two-year results of an open-label randomized comparison of everolimus-eluting stents and sirolimus-eluting stents.
by: Matthijs A Velders, et al.
Published: (2014-01-01)

Effects of Everolimus-Eluting Stents on the Left Ventricular Systolic and Diastolic Functions
by: MohammadSadegh Parsaee, et al.
Published: (2015-10-01)

Long-term follow-up of therapeutic efficacy of everolimus-eluting bioresorbable vascular scaffold in comparison to everolimus-eluting stent in treatment of chronic total occlusion guided by intracoronary imaging
by: Mohammad Abdallah Eltahlawi, et al.
Published: (2020-10-01)

Correction: Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents
by: Matthijs A. Velders, et al.
Published: (2013-01-01)

Clinical outcome of biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with diabetes
by: Ryota Kakizaki, et al.
Published: (2020-10-01)

Study to assess clinical outcomes of an everolimus-eluting stent (EES) versus a sirolimus-eluting stent (SES)
by: Amit Madaan, et al.
Published: (2015-12-01)

Paclitaxel-eluting stent (PES) versus everolimus-eluting stent (EES) in insulin requiring diabetics – Are the results different?
by: U. Kaul, et al.
Published: (2015-12-01)

Correction: Two-Year Results of an Open-Label Randomized Comparison of Everolimus-Eluting Stents and Sirolimus-Eluting Stents.
by: Matthijs A. Velders, et al.
Published: (2013-01-01)

The Twelve-Month Outcome of Biolimus Eluting Stent with Biodegradable Polymer Compared With an Everolimus Eluting Stent with Durable Polymer
by: Ahmad Separham, et al.
Published: (2011-11-01)

Twelve-month comparative analysis of clinical outcomes using biodegradable polymer–coated everolimus-eluting stents versus durable polymer–coated everolimus-eluting stents in all-comer patients
by: Atul Abhyankar, et al.
Published: (2019-03-01)

One-Year Outcome of Everolimus-Eluting Stents versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
by: Mohammad Alidoosti, et al.
Published: (2016-10-01)

Paclitaxel-eluting versus everolimus-eluting stents in patients with diabetes mellitus and coronary artery disease (TUXEDO India Study)
by: U. Kaul, et al.
Published: (2015-12-01)

Everolimus-Eluting Stents Reduce Monocyte Expression of Toll-Like Receptor 4
by: Mehriar Shokri, et al.
Published: (2015-12-01)

Clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents versus durable polymer everolimus-eluting Xience stents.
by: Da Hyon Lee, et al.
Published: (2017-01-01)

The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view
by: Sanchez OD, et al.
Published: (2014-12-01)

A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease
by: Bennett J, et al.
Published: (2013-06-01)

Comparison of everolimus-eluting and sirolimus-eluting coronary stents in 1-year clinical and angiographic follow-up: A retrospective cohort study
by: Ankur Gupta, et al.
Published: (2015-12-01)

Comparison of drug-eluting and bare metal stents for extracranial vertebral artery stenting
by: Damian Maciejewski, et al.
Published: (2019-09-01)

Spectral Analysis Related to Bare-Metal and Drug-Eluting Coronary Stent Implantation
by: Rose Mary Ferreira Lisboa da Silva, et al.
Published: (2014-08-01)

Outcomes of patients treated with the everolimus-eluting stent versus the zotarolimus-eluting stent in a consecutive cohort of patients at a tertiary medical center
by: Jerin M, et al.
Published: (2012-04-01)

One-year efficacy and safety of everolimus-eluting bioresorbable scaffolds in the setting of acute myocardial infarction.
by: Yongcheol Kim, et al.
Published: (2020-01-01)

Long‐term (beyond 5 years) clinical impact of Xience everolimus‐eluting stent implantation
by: Hiroaki Matsuda, et al.
Published: (2021-09-01)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug- Eluting Stents
by: Negar Faramarzi, et al.
Published: (2015-10-01)

Five-Year Comparative Efficacy of Everolimus-Eluting vs. Resolute Zotarolimus-Eluting Stents in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
by: Endrin Koni, et al.
Published: (2021-03-01)

Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program
by: R Michael Kirchner, et al.
Published: (2009-12-01)

How real is a threat of late thrombosis for drug-eluting stents? Stent comparison and focus on everolimus
by: V. P. Lupanov, et al.
Published: (2009-10-01)

Comparison of Bare metal Vs Drug eluting stents for in-stent Restenosis among Diabetics
by: Kakhaber Etsadashvili, et al.
Published: (2011-06-01)

Clinical Outcomes and Costs for Patients with Drug-Eluting Stents vs. Bare Metal Stents
by: Tzu-Ching Chen, et al.
Published: (2014)

Comparison of drug-eluting and bare-metal stents in patients with saphenous vein graft stenosis
by: Ahmed Zayed, et al.
Published: (2020-01-01)

Clinical Outcomes of Drug-Eluting versus Bare-Metal In-Stent Restenosis after the Treatment of Drug-Eluting Stent or Drug-Eluting Balloon: A Systematic Review and Meta-Analysis
by: Yi-Xing Yang, et al.
Published: (2020-01-01)

Cannot write session to /tmp/vufind_sessions/sess_oaed0suek1vjji0bg5g83233vb